Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Thursday 14 January, 2010

Lipoxen PLC

Patent Granted

RNS Number : 5219F
Lipoxen PLC
14 January 2010
 



FOR IMMEDIATE RELEASE

14 JANUARY 2010


Lipoxen plc

('Lipoxen' or 'the Company')


Lipoxen's Bio-Polymer Technology Granted Important US Patent 


- Extends life of the use of this natural polymer and extends cover in the World's largest market -


Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces today that it has been granted a new US patent for its PolyXen technology.  This technology is based on polysialic acid (PSA), (a polymer occurring naturally in humans) which extends a protein's active life, is biodegradable, non-immunogenic and non-toxic, and which is also therefore expected to avoid the toxicity attributed to polyethylene glycol in PEGylated protein drug candidates.


Polysialylation of therapeutic proteins i.e. the attachment of PSA on these molecules, is often hampered by random attachment of PSA molecules onto the protein. As a result, attached PSA can mask the active site of the therapeutic. In many cases, masking of activity can lead to complete loss of the protein's therapeutic function.


To avoid such problems, polysialylation is targeted on a specific domain on the protein, away from the active site. To that end, a specific domain is created by the introduction of a cysteine on the protein molecule (away from the active site) through protein engineering.


The US granted patent refers to the preparation of the PSA-linker-SH (cysteine)-protein construct. It has been shown that a number of therapeutic proteins which have been polysialylated, retain most of their activity as well as all the advantages of polysialylation i.e. improved drug performance and longer circulation time of the drug in the body.


In summary, the patent identifies that polysialylation, Lipoxen's PolyXen platform, is more effective in improving the therapeutic function of protein drugs.


Commenting on the patent grant, M. Scott Maguire, CEO of Lipoxen, said: "The new patent grant on this natural polymer which extends the active life of protein enhances our patent position in the world's largest pharmaceutical market and further supports our drive to become a leading innovator within the next generation biologic drug space.


Lipoxen has two potential billion dollar block-buster products in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO) both of which are based on this PolyXen technology. We are confident that this new patent will strengthen our commercial position as well as our capability to collaborate with partners." 


- Ends -


For further information please contact:


Lipoxen plc

+44 (0)20 7389 5015 

M. Scott Maguire, Chief Executive Officer




Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating, Claes Spång 




Noble & Company

+44 (0)20 7763 2200 

James Bromhead, Sam Reynolds  




Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon, Catherine Breen



Notes for Editors


About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms:


1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA


Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products.  


Lipoxen has multiple drug and vaccine programmes in development. Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for Factor VIII 


The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities. Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, Amgen and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the £2.9 million fundraising that the Company announced in May 2009 .


Lipoxen, which was founded in 1997, now trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com.



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDXLFFBFFZBBL